Literature DB >> 17951775

Protein production with recombinant baculoviruses in lepidopteran larvae.

Yi Liu1, Nathan DeCarolis, Nikolai van Beek.   

Abstract

With an increasing need for functional analysis of proteins, there is a growing demand for fast and cost-effective production of biologically active eukaryotic proteins. The baculovirus expression vector system is widely used, and in the vast majority of cases cultured insect cells have been the host of choice. A low cost alternative to bioreactor-based protein production exists in the use of live insect larvae as "mini bioreactors." In this chapter, we focus on Trichoplusia ni as the host insect for recombinant protein production, and explore three different methods of virus administration to the larvae. The first method is labor-intensive, as extracellular virus is injected into each larva, whereas the second lends itself to infection of large numbers of larvae via oral inoculation. While these first two methods require cultured insect cells for the generation of recombinant virus, the third relies on transfection of larvae with recombinant viral DNA and does not require cultured insect cells as an intermediate stage. We suggest that small-to mid-scale recombinant protein production (mg-g level) can be achieved in T. ni larvae with relative ease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951775

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Rotavirus A-specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo.

Authors:  Silvia Gómez-Sebastián; Maria C Nuñez; Lorena Garaicoechea; Carmen Alvarado; Marina Mozgovoj; Rodrigo Lasa; Alan Kahl; Andres Wigdorovitz; Viviana Parreño; José M Escribano
Journal:  BMC Biotechnol       Date:  2012-09-07       Impact factor: 2.563

2.  Production of a recombinant antibody fragment in whole insect larvae.

Authors:  Kevin P O'Connell; Elena Kovaleva; James H Campbell; Patricia E Anderson; Susan G Brown; David C Davis; James J Valdes; Richard W Welch; William E Bentley; Nikolai A van Beek
Journal:  Mol Biotechnol       Date:  2007-05       Impact factor: 2.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.